SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Burn, J; Gerdes, AM; Macrae, F; Mecklin, JP; Moeslein, G; Olschwang, S; Eccles, D; Evans, DG; Maher, ER; Bertario, L; et al. Burn, J; Gerdes, AM; Macrae, F; Mecklin, JP; Moeslein, G; Olschwang, S; Eccles, D; Evans, DG; Maher, ER; Bertario, L; Bisgaard, ML; Dunlop, MG; Ho, JW; Hodgson, SV; Lindblom, A; Lubinski, J; Morrison, PJ; Murday, V; Ramesar, R; Side, L; Scott, RJ; Thomas, HJ; Vasen, HF; Barker, G; Crawford, G; Elliott, F; Movahedi, M; Pylvanainen, K; Wijnen, JT; Fodde, R; Lynch, HT; Mathers, JC; Bishop, DT; CAPP2 Investigators (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet, 378 (9809). 2081 - 2087. ISSN 1474-547X https://doi.org/10.1016/S0140-6736(11)61049-0
SGUL Authors: Hodgson, Shirley Victoria

[img]
Preview
["document_typename_application/pdf; charset=binary" not defined] Published Version
Download (102kB) | Preview

Abstract

Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.

Item Type: Article
Additional Information: PMCID: PMC3243929
Keywords: Adenoma, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Chemoprevention, Colorectal Neoplasms, Hereditary Nonpolyposis, Dietary Carbohydrates, Double-Blind Method, Heterozygote, Humans, Starch
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cell Sciences (INCCCS)
Journal or Publication Title: Lancet
ISSN: 1474-547X
Dates:
DateEvent
17 December 2011Published
PubMed ID: 22036019
Web of Science ID: 22036019
Download EPMC Full text (HTML)
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/101069
Publisher's version: https://doi.org/10.1016/S0140-6736(11)61049-0

Actions (login required)

Edit Item Edit Item